Asahi Kasei Establishes Asahi Kasei Life Science to Drive its Bioprocess Businesses Forward
Asahi Kasei has established Asahi Kasei Life Science to consolidate and enhance its bioprocess businesses, effective April 1st. The new organization encompasses several key units including Planova™ virus removal filters, BioOptimal™ Microfilters, and testing services through ViruSure and Bionique Testing Laboratories, along with Bionova Scientific CDMO operations.
The company has recently expanded its capabilities with a scaled facility in Glenview, Illinois (2023), a new Planova™ assembly plant in Nobeoka, Japan (2024), and plans for a new plasmid DNA facility in Texas. These expansions aim to meet growing market demands and support innovation in bioprocess solutions, particularly for new modalities such as cell and gene therapy.
Asahi Kasei ha istituito Asahi Kasei Life Science per consolidare e migliorare le sue attività nel settore dei bioprocessi, a partire dal 1 aprile. La nuova organizzazione comprende diverse unità chiave tra cui i filtri per rimozione virus Planova™, i microfiltri BioOptimal™ e i servizi di testing attraverso ViruSure e Bionique Testing Laboratories, insieme alle operazioni CDMO di Bionova Scientific.
L'azienda ha recentemente ampliato le proprie capacità con un impianto su larga scala a Glenview, Illinois (2023), un nuovo stabilimento di assemblaggio Planova™ a Nobeoka, Giappone (2024) e ha in programma un nuovo impianto di DNA plasmidico in Texas. Queste espansioni mirano a soddisfare la crescente domanda di mercato e a sostenere l'innovazione nelle soluzioni di bioprocessi, in particolare per nuove modalità come la terapia cellulare e genica.
Asahi Kasei ha establecido Asahi Kasei Life Science para consolidar y mejorar sus negocios de bioprocesos, a partir del 1 de abril. La nueva organización abarca varias unidades clave, incluidos los filtros de eliminación de virus Planova™, los microfiltros BioOptimal™ y los servicios de pruebas a través de ViruSure y Bionique Testing Laboratories, junto con las operaciones CDMO de Bionova Scientific.
La empresa ha ampliado recientemente sus capacidades con una instalación a gran escala en Glenview, Illinois (2023), una nueva planta de ensamblaje Planova™ en Nobeoka, Japón (2024) y planes para una nueva instalación de ADN plasmídico en Texas. Estas expansiones tienen como objetivo satisfacer la creciente demanda del mercado y apoyar la innovación en soluciones de bioprocesos, particularmente para nuevas modalidades como la terapia celular y génica.
아사히 카세이는 4월 1일부터 생명과학 부문을 통합하고 강화하기 위해 아사히 카세이 생명과학을 설립했습니다. 새로운 조직은 Planova™ 바이러스 제거 필터, BioOptimal™ 마이크로필터, ViruSure 및 Bionique Testing Laboratories를 통한 테스트 서비스, Bionova Scientific CDMO 운영을 포함한 여러 주요 단위를 포함합니다.
회사는 최근 일리노이주 글렌뷰에 대규모 시설(2023)을 확장하고, 일본 노베오카에 새로운 Planova™ 조립 공장을 (2024) 설립했으며, 텍사스에 새로운 플라스미드 DNA 시설을 계획하고 있습니다. 이러한 확장은 증가하는 시장 수요를 충족하고 세포 및 유전자 치료와 같은 새로운 방식의 생물 프로세스 솔루션 혁신을 지원하는 것을 목표로 합니다.
Asahi Kasei a établi Asahi Kasei Life Science pour consolider et améliorer ses activités de bioprocédés, à compter du 1er avril. La nouvelle organisation comprend plusieurs unités clés, y compris les filtres de suppression de virus Planova™, les microfiltres BioOptimal™ et les services de test via ViruSure et Bionique Testing Laboratories, ainsi que les opérations CDMO de Bionova Scientific.
L'entreprise a récemment élargi ses capacités avec une installation à grande échelle à Glenview, Illinois (2023), une nouvelle usine d'assemblage Planova™ à Nobeoka, Japon (2024) et prévoit une nouvelle installation d'ADN plasmidique au Texas. Ces expansions visent à répondre à la demande croissante du marché et à soutenir l'innovation dans les solutions de bioprocédés, en particulier pour de nouvelles modalités telles que la thérapie cellulaire et génique.
Asahi Kasei hat Asahi Kasei Life Science gegründet, um seine Bioprozessgeschäfte zu konsolidieren und zu verbessern, mit Wirkung zum 1. April. Die neue Organisation umfasst mehrere wichtige Einheiten, darunter Planova™ Virusentfernungsmodule, BioOptimal™ Mikrofilter und Testdienstleistungen über ViruSure und Bionique Testing Laboratories sowie die CDMO-Operationen von Bionova Scientific.
Das Unternehmen hat kürzlich seine Kapazitäten mit einer großflächigen Einrichtung in Glenview, Illinois (2023), einem neuen Planova™ Montagewerk in Nobeoka, Japan (2024) und Plänen für eine neue Plasmid-DNA-Anlage in Texas erweitert. Diese Erweiterungen zielen darauf ab, die wachsende Marktnachfrage zu decken und Innovationen in Bioprozesslösungen zu unterstützen, insbesondere für neue Modalitäten wie Zell- und Gentherapie.
- Strategic expansion with new facilities in Illinois (2023) and Japan (2024)
- New plasmid DNA facility planned in Texas to capture growth in cell and gene therapy market
- Portfolio diversification through recent acquisitions (ViruSure, Bionique, Bionova)
- Growing market presence in high-demand bioprocess products and services
- None.
Serving as a premium partner for pharmaceutical companies by contributing to the safety and productivity of their manufacturing process
Ken Shinomiya, President of Asahi Kasei Life Science
As part of the evolving pharmaceutical ecosystem, where multiple stakeholders are involved in drug development and manufacturing, Asahi Kasei’s bioprocess-related business units have operated under Asahi Kasei Life Science since April 1st of this year. This includes virus removal filters Planova™ and Microfilters BioOptimal™, its contract research organization (CRO) testing services performed by ViruSure of
Asahi Kasei Life Science covers a broad range of bioprocess products and services. Planova™ virus removal filters and equipment used in the manufacturing process of biotherapeutic products contribute to improved safety and productivity for antibody drugs, plasma derivatives, and nucleic acid drugs. Recently launched products such as Planova™’s FG1 and THESYS™ SCS and ACS Columns are already highly valued by customers.
In line with the strategic expansion of its Healthcare business sector, Asahi Kasei has expanded its production and service capabilities for its bioprocess-related business throughout the past years. In 2023, the company scaled its facility in
“I am thrilled to announce the start of operations at Asahi Kasei Life Science, which began on April 1,” said Ken Shinomiya, President of Asahi Kasei Life Science. “Focused on the field of life science centered on the bioprocess business, we aim to expand as part of the growing Healthcare sector business, the main growth driver of the Asahi Kasei Group. As a trusted premium partner, we are dedicated to shaping the future of the pharmaceutical industry—delivering innovative, reliable solutions that drive lasting impact and empower our clients to thrive.”
To learn more about Asahi Kasei Life Science, visit [https://www.asahi-kasei.co.jp/lifescience/]
About Asahi Kasei
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 49,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world’s challenges through its three business sectors of Material, Homes, and Healthcare. For more information, visit www.asahi-kasei.com.
Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250408291750/en/
North America Contact:
Asahi Kasei America Inc.
Christian OKeefe
christian.okeefe@ak-america.com
Europe Contact:
Asahi Kasei Europe GmbH
Sebastian Schmidt
sebastian.schmidt@asahi-kasei.eu
Source: Asahi Kasei Corp.
FAQ
What is the purpose of Asahi Kasei's new Life Science division (AHKSY)?
What key products and services does Asahi Kasei Life Science offer?
What recent facility expansions has Asahi Kasei (AHKSY) completed?
How is Asahi Kasei (AHKSY) expanding into the plasmid DNA market?
